FCCC LOGO Faculty Publications
Goetz MP , Gradishar WJ , Anderson BO , Abraham J , Aft R , Allison KH , Blair SL , Burstein HJ , Dang C , Elias AD , Farrar WB , Giordano SH , Goldstein LJ , Isakoff SJ , Lyons J , Marcom PK , Mayer IA , Moran MS , Mortimer J , O'Regan RM , Patel SA , Pierce LJ , Reed EC , Rugo HS , Sitapati A , Smith KL , Smith ML , Soliman H , Telli ML , Ward JH , Young JS , Shead DA , Kumar R
NCCN Guidelines Insights: Breast Cancer, Version 3.2018
J Natl Compr Canc Netw. 2019 Feb;17(2) :118-126
Back to previous list
Abstract
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
Notes
1540-1413 Goetz, Matthew P Gradishar, William J Anderson, Benjamin O Abraham, Jame Aft, Rebecca Allison, Kimberly H Blair, Sarah L Burstein, Harold J Dang, Chau Elias, Anthony D Farrar, William B Giordano, Sharon H Goldstein, Lori J Isakoff, Steven J Lyons, Janice Marcom, P Kelly Mayer, Ingrid A Moran, Meena S Mortimer, Joanne O'Regan, Ruth M Patel, Sameer A Pierce, Lori J Reed, Elizabeth C Rugo, Hope S Sitapati, Amy Smith, Karen Lisa Smith, Mary Lou Soliman, Hatem Telli, Melinda L Ward, John H Young, Jessica S Shead, Dorothy A Kumar, Rashmi Journal Article United States J Natl Compr Canc Netw. 2019 Feb;17(2):118-126. doi: 10.6004/jnccn.2019.0009.